10-Q: 89bio Reports Wider Q2 Loss, Advances MASH Trials

89bio, a clinical-stage biopharmaceutical company, reported a significantly wider net loss in Q2 2025 due to increased R&D and G&A expenses, while advancing its lead MASH and SHTG product candidates.

Summary

• Net loss for the six months ended June 30, 2025, widened to $182.8 million, compared to $99.7 million for the same period in 2024.
• Research and development (R&D) expenses increased by $76.0 million to $168.3 million for the six months ended June 30, 2025, primarily due to a $40.0 million non-recurring payment to BiBo for manufacturing facility construction and a $32.2 million increase in clinical development costs for Phase 3 MASH trials.
• General and administrative (G&A) expenses rose by $5.0 million to $23.4 million for the six months ended June 30, 2025, driven by increased personnel-related costs.
• Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025, which is expected to fund operations for at least one year from the filing date.
• Enrollment for the Phase 3 ENTRUST trial in SHTG was completed in December 2024, with topline data now anticipated in Q1 2026.
• Phase 3 ENLIGHTEN-Fibrosis (F2-F3) and ENLIGHTEN-Cirrhosis (F4) trials for MASH are actively enrolling patients, with topline histology data expected in H1 2027 and 2028, respectively.
• An amendment to the collaboration agreement with BiBo in June 2025 increased the total commitment for the commercial manufacturing facility to $175.0 million, with a final $13.5 million payment due upon facility completion, estimated in 2026.

Sentiment

Score: 4

Explanation: The company maintains a strong cash position, which is crucial for its long clinical development timelines, and its lead MASH program is progressing with significant regulatory designations. However, the substantial increase in net losses and operating expenses, coupled with the delay in SHTG trial data and the unresolved Israeli tax dispute, introduce considerable financial and operational uncertainty. The competitive landscape and challenges in patient enrollment for MASH trials also weigh on the outlook.

Positives

• Strong cash, cash equivalents, and marketable securities balance of $561.2 million as of June 30, 2025, providing a cash runway of at least one year.
• Lead product candidate, pegozafermin, is advancing through Phase 3 clinical development for MASH and SHTG.
• Pegozafermin has received Breakthrough Therapy Designation from the FDA and Priority Medicines Designation (PRIME) from the EMA for MASH, potentially expediting development and review.
• Enrollment for the Phase 3 ENTRUST trial in SHTG was completed in December 2024, a significant milestone.
• The collaboration agreement with BiBo for the commercial manufacturing facility has been amended to limit future financial exposure for additional construction costs beyond the agreed $175.0 million.
• Scalability of the manufacturing process for pegozafermin was successfully demonstrated in Q4 2024, supporting future commercial supply.

Negatives

• Net loss significantly widened to $182.8 million for the six months ended June 30, 2025, from $99.7 million in the prior year period, reflecting increased operating expenses.
• Research and development expenses increased substantially, driven by a $40.0 million non-recurring payment for manufacturing and higher clinical development costs.
• Topline data for the SHTG ENTRUST trial is now expected in Q1 2026, a delay from previous expectations for an interim Week 26 readout.
• Experienced a higher than anticipated level of screen failures in the ENLIGHTEN-Fibrosis (F2/F3) clinical trial, potentially due to increasing usage of GLP-1 based therapies, which could delay enrollment.
• Received a formal assessment order from the Israeli Tax Authority (ITA) asserting a tax liability of approximately $26.0 million and related penalties of $3.9 million, with a recorded liability of $5.3 million for an unrecognized tax benefit, posing a significant financial uncertainty.

Risks

• As a clinical-stage biopharmaceutical company with a limited operating history and no approved products, the company has incurred significant and increasing operating losses and may never be profitable.
• Business success is highly dependent on pegozafermin, the only product candidate under clinical development, which has not completed a pivotal trial.
• Clinical drug development is a lengthy, expensive, and uncertain process, and prior preclinical/clinical trial results are not necessarily predictive of future outcomes.
• Substantial additional capital will be required to finance operations, which may not be available on acceptable terms or at all, potentially hindering development and commercialization.
• Delays in clinical testing could adversely affect commercial prospects, increase costs, and harm the business.
• Difficulties in enrolling patients in clinical trials, particularly for MASH due to diagnostic challenges and GLP-1 therapy usage, could delay or adversely affect clinical development.
• Reliance on third-party manufacturers and vendors (e.g., BiBo, BTPH) exposes the company to risks of supply disruption, increased costs, and compliance failures, including geopolitical risks related to manufacturing in China (e.g., BIOSECURE Act, tariffs).
• Pegozafermin and future product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit the commercial label.
• Regulatory requirements for MASH and SHTG are difficult to predict and may change, impacting the timing and costs of clinical development.
• Lack of efficacy or adverse events in clinical trials conducted by third parties developing similar FGF product candidates could negatively affect the company's stock price and development program.
• Interim, topline, and preliminary data from clinical trials are subject to change as more patient data become available and are subject to audit and verification.
• The manufacture of biologic products is complex and subject to many risks, which could substantially increase costs and limit product supply.
• The company faces substantial competition from multinational pharmaceutical companies and specialized biotechnology companies, including those developing GLP-1 therapies and other MASH treatments (e.g., Rezdiffra).
• Unstable market and economic conditions, inflation, interest rate fluctuations, natural disasters, public health crises, and geopolitical events (e.g., Ukraine, Israel) may have serious adverse consequences.
• The Loan Agreement contains covenants that could adversely affect operations, and an event of default could force early repayment of indebtedness.
• Inability to obtain regulatory approvals for pegozafermin or future product candidates would substantially harm the business.
• Even if regulatory approval is received, products may face future development and regulatory difficulties, including post-marketing study requirements or potential revocation of approval.
• Product candidates regulated as biologics may be subject to biosimilar competition sooner than anticipated due to the BPCIA.
• Current and future legislation (e.g., Inflation Reduction Act of 2022) may increase the difficulty and cost of obtaining marketing approval and commercializing drugs, and affect pricing.
• Healthcare insurance coverage and reimbursement may be limited or unavailable, making it difficult to sell products profitably.
• Ability to obtain and maintain intellectual property protection for products and technologies is crucial and subject to uncertainty, challenges, and potential infringement claims.
• Reliance on licenses from Teva and ratiopharm for glycoPEGylation technology means termination or loss of rights under these agreements would materially and adversely affect development and commercialization.
• The price of common stock may be volatile and fluctuate significantly due to various factors, including business developments, market trends, and competitor announcements.
• Sales of common stock, or the perception of such sales, or issuance of shares upon warrant exercise could depress the stock price.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• Directors, executive officers, and significant stockholders have substantial control, potentially limiting influence over stockholder approval matters, including change of control.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud, and inability to maintain effective internal control over financial reporting could negatively impact financial reports and stock price.
• The company's amended and restated certificate of incorporation, bylaws, and Delaware law could prevent a third party from acquiring the company.
• Exclusive forum provisions in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Adverse legislative or regulatory tax changes (e.g., One Big Beautiful Bill Act) could negatively impact financial condition.
• Ability to use net operating loss carryforwards and other tax attributes may be limited, and tax assessments (e.g., Israeli Tax Authority matter) could impact them and financial results.
• Litigation costs and outcomes could have a material adverse effect on the business.

Future Outlook

The company expects operating losses to continue and increase for the foreseeable future as clinical development activities for pegozafermin progress. Existing cash, cash equivalents, and marketable securities of $561.2 million as of June 30, 2025, are believed to be sufficient to fund planned operating expenses for at least one year from the filing date. However, substantial additional capital will be required to complete development, obtain marketing approval, and commercialize pegozafermin and any future product candidates. Topline data from the ENTRUST trial for SHTG is now expected in Q1 2026, and topline histology data from the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials for MASH are anticipated in H1 2027 and 2028, respectively. The company continues to monitor international trade policies and potential changes to import tariffs that could impact manufacturing costs.

Management Comments

• We believe our existing cash, cash equivalents and marketable securities of $561.2 million as of June 30, 2025 will be sufficient to fund our planned operating expense requirements for a period of at least one year from the issuance date of these condensed consolidated financial statements.
• We expect operating losses to continue and increase for the foreseeable future as we progress our clinical development activities for our product candidates.
• We now expect to report topline data from ENTRUST in the first quarter of 2026.
• Construction of the Commercial Facility remains on schedule to support a planned Biologics License Application (BLA) filing.

Industry Context

The biopharmaceutical industry, particularly in liver and cardio-metabolic diseases like MASH and SHTG, is highly competitive and rapidly evolving. 89bio's pegozafermin, an FGF21 analog, is in Phase 3 development, competing with other companies like Novo Nordisk, Akero Therapeutics, Inc., and Boston Pharmaceuticals also developing FGF21 candidates. The recent approval of Rezdiffra (Madrigal Pharmaceuticals) for MASH sets a new standard and could impact patient enrollment in clinical trials for other MASH therapies, as patients may opt for an approved drug. The increasing use of GLP-1 based therapies for obesity and Type 2 diabetes also presents a dynamic, as these therapies may exert similar effects to pegozafermin in MASH, potentially affecting trial enrollment and future market dynamics. 89bio's strategy to enroll patients on background GLP-1 therapies aims to evaluate incremental benefits. The company's diversified manufacturing strategy, including a facility in China, reflects broader industry efforts to enhance supply chain resilience but also exposes it to geopolitical risks and trade policy changes, such as the proposed BIOSECURE Act.

Comparison to Industry Standards

• 89bio's pegozafermin is an FGF21 analog, a class of drugs also being developed by competitors such as Novo Nordisk, Akero Therapeutics, Inc., and Boston Pharmaceuticals for MASH, indicating a shared therapeutic approach within the industry.
• The approval of Rezdiffra (resmetirom) by Madrigal Pharmaceuticals for MASH sets a precedent for regulatory pathways and potential market expectations, which 89bio's pegozafermin will compete against if approved.
• The company's observation of higher screen failures in its ENLIGHTEN-Fibrosis trial, potentially driven by increasing GLP-1 based therapy usage, highlights a broader industry challenge as GLP-1s gain traction in metabolic diseases, potentially impacting patient populations for MASH trials.
• 89bio's strategy to evaluate pegozafermin in patients on background GLP-1 therapies is a direct response to evolving treatment landscapes, aiming to demonstrate incremental benefit over a growing standard of care, similar to how other companies might explore combination therapies.

Management Changes

Legal Proceedings

• The Israeli Tax Authority (ITA) is auditing the Israeli subsidiary for tax years 2018 through 2021, related to a 2019 reorganization and intercompany transactions.
• A formal assessment order was received in Q2 2025, seeking to recharacterize an intercompany transfer of intellectual property rights as a taxable sale, asserting a tax liability of approximately $26.0 million and related penalties of $3.9 million.
• The company disagrees with the ITA's positions and has filed an appeal; a liability for unrecognized tax benefit of $5.3 million has been recorded as of June 30, 2025.
• The ultimate resolution of this matter is uncertain and could materially and adversely impact financial condition and results of operations.

Stakeholder Impact

• **Shareholders:** Experienced dilution from recent public offerings and ATM sales, with potential for further dilution from future capital raises. The stock price is subject to volatility due to clinical trial outcomes, regulatory decisions, and financial performance. Long-term value depends on successful development and commercialization of pegozafermin.
• **Employees:** Increased headcount in R&D and G&A functions, indicating growth in operations. Stock-based compensation is a significant component of employee remuneration. The company faces the risk of not attracting and retaining highly skilled personnel in a competitive industry.
• **Customers (Future):** Potential new therapeutic options for patients suffering from MASH and SHTG, addressing significant unmet medical needs.
• **Suppliers & Creditors:** Continued reliance on third-party manufacturers (e.g., BiBo, BTPH) for product supply. The company has a term loan facility with K2 HealthVentures LLC, with obligations secured by substantially all assets excluding intellectual property. The amendment to the BiBo collaboration agreement limits future financial exposure for facility construction costs.
• **Teva Pharmaceutical Industries Ltd.:** The company is obligated to make future milestone and royalty payments to Teva upon achievement of specified commercial milestones and worldwide net sales of pegozafermin, aligning their interests in the product's success.

Next Steps

• Report topline data from the Phase 3 ENTRUST trial for SHTG in Q1 2026.
• Continue active enrollment for the Phase 3 ENLIGHTEN-Fibrosis (F2-F3) and ENLIGHTEN-Cirrhosis (F4) trials for MASH.
• Anticipate reporting topline histology data from ENLIGHTEN-Fibrosis in H1 2027.
• Anticipate reporting topline histology data from ENLIGHTEN-Cirrhosis in 2028.
• Continue treatment for patients in ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis for collection of outcome events to support potential full approval.
• Complete the BiBo commercial manufacturing facility, with a final $13.5 million milestone payment due upon completion (estimated 2026).
• Continue to pursue various avenues to resolve the Israeli Tax Authority matter through administrative and judicial channels.
• Maintain minimum unrestricted cash, cash equivalents, and marketable securities equal to 5.0 times the average change in such balances over the trailing three-month period, commencing January 1, 2026, as per the Loan Agreement.

Key Dates

Recommendation

The company maintains a robust cash position of $561.2 million, providing a runway of over one year, which is critical for a clinical-stage biopharmaceutical company. The lead candidate, pegozafermin, is progressing into pivotal Phase 3 trials for MASH, supported by Breakthrough Therapy and PRIME designations, indicating significant regulatory recognition. However, the substantial increase in net losses and operating expenses reflects a high burn rate. The delay in topline data for the SHTG trial and the ongoing, material tax dispute with the Israeli Tax Authority introduce notable uncertainties and financial risks. While the long-term potential in MASH is significant, the competitive landscape, the impact of GLP-1 therapies on trial enrollment, and the extended timelines for MASH data (2027-2028) suggest that profitability is distant. Given the mixed signals of strong financial backing for development against increasing losses and specific program delays, a 'hold' recommendation is appropriate, advising investors to monitor clinical progress and resolution of financial contingencies before making further commitments.

Keywords

Biopharmaceutical, MASH, NASH, SHTG, Pegozafermin, FGF21, Clinical Trials, Liver Disease, Cardio-metabolic, Drug Development, SEC Filing, Biotechnology